Aptevo Therapeutics

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.

SEATTLE, WA / ACCESSWIRE / August 4, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical stage biotechnology company focused on developing novel immuno-oncology therapeutics, today announced the closing of its previously announced public offering of 2,221,550 shares of common stock at a purchase price of $0.62 per share, Pre-Funded Warrants to purchase up to an aggregate of 5,842,967 shares of common stock at a purchase price of $0.619 per Pre-Funded Warrant, Series A Warrants to purchase up to an aggregate of 8,064,517 shares of common stock and Series B Warrants to purchase up to an aggregate of 8,064,517 shares of common stock. The Pre-Funded Warrants have an exercise price of $0.001, are immediately exercisable and may be exercised at any time until exercised in full.

Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering

Aptevo Therapeutics (NASDAQ: APVO ) stock is sliding lower on Wednesday after the biotechnology company announced a public share offering. The APVO stock offering has the company selling 8,064,517 shares at a price of 62 cents per share.

Why Is Aptevo Therapeutics (APVO) Stock Down 33% Today?

SEATTLE, WA / ACCESSWIRE / August 1, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical stage biotechnology company focused on developing novel immuno-oncology therapeutics, today announced that the Company has entered into definitive agreements with healthcare-focused institutional investors for the purchase and sale of 8,064,517 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.62 per share. The Company further agreed to issue to the investors Series A Warrants to purchase up to an aggregate of 8,064,517 shares of common stock and Series B Warrants to purchase up to an aggregate of 8,064,517 shares of common stock.

Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering

Chimerix

Flexible Solutions

Glory Star New Media Group Holdings Ltd

Optex Systems Holdings Inc

X Financial - ADR

Yirendai Ltd. Sponsored

Millionaire-maker penny stocks, as you might guess from the title does not represent a universally accessible sector. While these ideas can possibly make you rich, they can just as easily make you poor.

7 Millionaire-Maker Penny Stocks to Buy Before the Window Closes

Phase 2 Trials in Relapsed/Refractory and Frontline Settings Planned, APVO436 to be administered in Combination with Emerging Standard of Care New Data Adds to Growing Body of Clinical Evidence in Support of APVO436 Clinical Potential SEATTLE, WA / ACCESSWIRE / July 18, 2023 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (Nasdaq;APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that its bispecific AML drug candidate APVO436, in combination with emerging standard of care venetoclax and azacitidine, achieved positive duration of remission results in its Phase 1b dose escalation trial. The Company is also providing an update of its APVO436 Phase 2 program design that will include both frontline and relapsed/refractory trials beginning later in the second half of 2023.

Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML

Company Achieves Multiple Clinical and Preclinical Milestones and Raises $9.7 Million in Non-Dilutive Funding, Eliminates Balance Sheet Debt Introduces Novel Compound APVO711, Dual Mechanism of Action Includes Both Checkpoint Inhibitor and T Cell Stimulator SEATTLE, WA / ACCESSWIRE / May 11, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ended March 31, 2023 and provided a business update. First Quarter Highlights Raised $9.7 million in non-dilutive funding, extending cash runway beyond 12 months A portion of the proceeds was used to fully repay the existing debt facility on the Company's balance sheet The Company achieved this by closing a transaction for the complete sale of all future IXINITY deferred payments and a portion of IXINITY milestones to XOMA Corporation Announced plans to initiate its Phase 2 program in the second half of 2023 to further evaluate APVO436, a bispecific CD3xCD123 ADAPTIR molecule, in combination with venetoclax and azacytidine in frontline and relapsed/refractory venetoclax treatment naïve patients with acute myeloid leukemia (AML).

Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update

Company Achieves Multiple Clinical and Scientific Milestones in 2022, Poised for APVO436 Phase 2 in AML 2H23, ALG.APV-527 dosing initiated 1Q23 for Solid Tumors SEATTLE, WA / ACCESSWIRE / March 30, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the year ended December 31, 2022 and business highlights. 2022 Highlights APVO436 (Acute Myeloid Leukemia) In December 2022 we announced that APVO436, in combination with venetoclax and azacitidine, demonstrated substantial clinical activity and a favorable safety and tolerability profile in adult venetoclax treatment naïve AML patients.

Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update

Completes Sale of IXINITY Deferred Payments and Portion of Milestones from Medexus to XOMA Corporation SEATTLE, WA / ACCESSWIRE / March 30, 2023 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that the Company has raised $9.6 million in non-dilutive funding, extending its cash runway beyond 12 months with an additional $50,000 possible based on IXINITY sales in Q123. Aptevo raised this funding by closing a transaction for the complete sale of all future IXINITY deferred payments and a portion of IXINITY milestones to XOMA Corporation.

Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding

Beam Therapeutics

Dynavax Technologies

iTeos Therapeutics, Inc.

Kiniksa Pharmaceuticals Ltd

Vir Biotechnology

Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.

The Top 7 Growth Stocks in Biotech

New PD-L1 x CD40 Candidate Built on Proprietary ADAPTIR™ Platform, Enters Pre-Clinical Pipeline SEATTLE, WA / ACCESSWIRE / January 9, 2023 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that the Company has filed a provisional patent with the U.S. Patent and Trademark Office (USPTO) pertaining to an anti-PD-L1 x anti-CD40 compound, APVO711, with the potential to fight a range of solid malignancies such as head and neck squamous cell carcinoma, melanoma, and carcinomas of the lung, gastrointestinal tract and colon. The Company plans to initiate pre-clinical studies this year.

Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors

Shares of Aptevo Therapeutics Inc. APVO, -0.20% soared 107% in premarket trading on Monday after the company said a combination of its experimental therapy with azacitidine and venetoclax produced a clinical benefit in 16 patients with acute myeloid leukemia who haven't been previously treated with venetoclax in an early stage clinical trial. Azacitidine and venetoclax are commonly used to treat AML.

Aptevo's stock rallies 107% after sharing preliminary data about experimental leukemia treatment

Aptevo Therapeutics Plans a Phase 2 Trial in 2H23 in Frontline and Relapsed/Refractory Patients who are Venetoclax Treatment Naïve Data Demonstrating APVO436 to be Safe and Well-Tolerated and Clinically Active Among AML Patients in Both Combination and Monotherapy Regimens Presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition SEATTLE, WA / ACCESSWIRE / December 12, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that APVO436, in combination with venetoclax and azacitidine, achieved a 100% clinical benefit rate (CBR) in venetoclax treatment naïve AML patients. The data, which was presented in a poster session at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, also showed that APVO436, when given in combination with this standard-of-care regimen, was observed to be generally safe and well tolerated.

100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)

Company to Present New APVO436 Expansion Phase Trial Data at Upcoming American Society of Hematology Annual Meeting and Exposition SEATTLE, WA / ACCESSWIRE / November 10, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results and business highlights for the quarter ended September 30, 2022. Business Highlights Presenting new Phase 1b expansion trial data for APVO436 in the treatment of Acute Myeloid Leukemia (AML) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 10-13 in New Orleans, Louisiana The poster, entitled " Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 ADAPTIR™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome" ​ will be presented on Sunday, December 11, 2022 from 6:00 PM-8:00 PM Central time Announced that the US Food and Drug Administration (FDA) issued a "may proceed" notification for the ALG.APV-527 investigational new drug application (IND), allowing the initiation of clinical trials evaluating the compound for the treatment of 5T4-expressing tumors in multiple solid tumor types Continued dosing patients in the Company's Phase 1b expansion program evaluating APVO436 for the treatment of acute myeloid leukemia in both combination therapy and monotherapy "We are very excited to present our APVO436 expansion phase data at the upcoming ASH meeting, fulfilling a promise we made earlier in the year and further underscoring our enthusiasm for the compound and rationale for its continued advancement in the clinic.

Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Company to Present New Data from On-Going Phase 1b Trial Evaluating Lead Candidate APVO436 for the Treatment of Acute Myeloid Leukemia SEATTLE, WA / ACCESSWIRE / November 3, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced acceptance of a poster presentation at 64th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 10-13 in New Orleans, Louisiana. Details of the presentation, which will be presented live, are as follows: Title: "Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 ADAPTIR™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome" Date/Time: Sunday, December 11, 2022, 6:00 PM-8:00 PM Presenter: Justin M.

Aptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition

SEATTLE, WA / ACCESSWIRE / August 11, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results and business highlights for the quarter ended June 30, 2022. Business Highlights On June 9, 2022, the Company reported positive preliminary data from the on-going Phase 1b trial evaluating lead candidate, APVO436 for the treatment of acute myeloid leukemia (AML).

Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-evaluable Patients Treated to Date Cohort 3 Monotherapy Patient Achieved Bone Marrow Complete Remission Company Also Reports Myelodysplastic Syndrome Patient Enrolled in Dose Escalation Trial Remains Stable and on APVO436 After 18 Months of Treatment SEATTLE, WA / ACCESSWIRE / June 9, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced new remission data on four additional patients. The new data includes one patient who achieved a complete remission (CR), one patient who achieved a complete remission with incomplete hematologic recovery (CRi) and two patients who achieved bone marrow complete remissions, or morphological leukemia-free state (MLFS), in the Company's on-going multi-cohort, multi-center Phase 1b expansion trial evaluating APVO436 for the treatment of acute myeloid leukemia (AML).

Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia

SEATTLE, WA / ACCESSWIRE / May 12, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results and business highlights for the quarter ended March 31, 2022. Business Highlights Earned and collected a $10 million non-dilutive milestone payment related to 2021 sales of RUXIENCE®.

Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

Preclinical Data Support Potential for APVO442 in Difficult-to-Treat Types of Prostate Cancer, Including Metastatic Castration-Resistant Disease SEATTLE, WA / ACCESSWIRE / April 12, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the presentation of preclinical data for APVO442 in a poster session at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, LA. APVO442 is a bispecific therapeutic candidate targeting prostate-specific maturation antigen (PSMA) and CD3 designed to redirect the patient's T cell-mediated tumor-fighting responses against PSMA-expressing solid tumors (prostate cancer).

APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting

Patients in Both Monotherapy and Combination Arms in Multi-Cohort Trial Have Achieved Transplant Eligible Status SEATTLE, WA / ACCESSWIRE / March 29, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that a patient with relapsed/refractory acute myeloid leukemia or AML in a monotherapy arm of its on-going Phase 1b trial evaluating adult patients with AML, has received an allogeneic stem cell transplant subsequent to receiving APVO436 and experiencing significant reduction in bone marrow blasts. This follows the Company's previous announcement that a patient receiving combination therapy is also moving to transplant after one cycle of therapy.

Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia

Aptevo Therapeutics Inc (NASDAQ: APVO) shares are trading higher Thursday after the company reported 2021 financial results.  Aptevo said royalty revenue totaled $12.3 million in 2021, up from royalties of $4.3 million in 2020.

Why Did Aptevo Therapeutics Stock Jump 25% Today?

SEATTLE, WA / ACCESSWIRE / March 24, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported its financial results for the year ended December 31, 2021 and provided 2021 business highlights. "2021 was an eventful year for Aptevo Therapeutics.

Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update

Aptevo Therapeutics Inc APVO earned a $10 million non-dilutive milestone payment related to 2021 sales of Ruxience, under the terms of its royalty purchase agreement with HealthCare Royalty Management LLC. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Why Are Aptevo Therapeutics Shares Trading Higher Today?

APVO436 Phase 1b Trial for Acute Myeloid Leukemia Adds New Site Complete Remission Patient to Advance to Transplant SEATTLE, WA / ACCESSWIRE / February 9, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that the Company has earned a $10 million non-dilutive milestone payment related to 2021 sales of RUXIENCE®. Additionally, based on RUXIENCE 2021 fourth quarter and full-year sales results, the Company is optimistic about the possibility of earning additional non-dilutive milestones totaling $22.5 million over the next two years.

Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update

Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022

LUND, Sweden and SEATTLE, Dec. 15, 2021 /PRNewswire/ -- Alligator Bioscience AB ("Alligator") and Aptevo Therapeutics ("Aptevo") (NASDAQ: APVO) today announced publication of an article in the December 15, 2021, issue of the peer-reviewed journal, Nature Communications on the mechanism of action of CD137 (4-1BB) targeting bispecific antibodies. Nature Communications is an open access, multidisciplinary journal dedicated to publishing high-quality research in all areas of the biological, health, physical, chemical and Earth sciences.

News for Aptevo Therapeutics Stock (APVO)